Welcome to our dedicated page for Apogee Therapeutics SEC filings (Ticker: APGE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Apogee Therapeutics, Inc. (APGE) SEC filings page on Stock Titan aggregates the company’s U.S. Securities and Exchange Commission disclosures, providing insight into its status as a Nasdaq-listed, clinical-stage biotechnology issuer. These documents include current reports on Form 8-K, financial statements, equity offering details and other regulatory information that frame Apogee’s development and financing activities in inflammatory and immunology (I&I) therapeutics.
Apogee’s Forms 8-K illustrate how the company reports material events such as quarterly financial results, interim clinical data for programs like APG777 and APG333, and the terms of underwritten public offerings of common stock and pre-funded warrants under an effective shelf registration statement. Selected 8-Ks also summarize outcomes of the annual meeting of stockholders, including director elections, auditor ratification and advisory votes on executive compensation frequency.
Through these filings, investors can review Apogee’s reported research and development and general and administrative expenses, net losses, cash and marketable securities balances, and the impact of capital raises on its operating runway. Offering-related filings describe underwriting agreements, option exercises by underwriters, pre-funded warrant terms and associated legal opinions, all of which help clarify the structure of Apogee’s capital formation.
On Stock Titan, users can access Apogee’s SEC filings alongside AI-powered summaries that explain the key points of lengthy documents such as earnings-related 8-Ks and registration statement updates. This includes highlighting where the company discusses clinical trial timelines, interim data disclosures, and other items relevant to its I&I pipeline. The filings page also surfaces exhibits like press releases and data presentations incorporated into 8-Ks, as well as cover page information confirming that Apogee’s common stock trades on The Nasdaq Global Market under the symbol APGE.
For those monitoring regulatory developments, capital structure changes or disclosure around programs such as APG777, APG279 and APG333, the SEC filings page offers an organized view of Apogee’s official communications with regulators and investors.
Apogee Therapeutics Chief Medical Officer Carl Dambkowski exercised stock options and sold shares in a planned transaction. He exercised options covering 4,125 shares of common stock at an exercise price of $22.86 per share and received 4,125 shares.
On the same date, he sold a total of 5,500 common shares in open-market trades at weighted average prices of about $84.31, $85.33, and $85.89, leaving him with 208,398 directly held shares. The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 22, 2025. A related option grant represents the right to purchase 175,345 shares vesting monthly through December 18, 2027, subject to continued service.
Apogee Therapeutics, Inc. Chief Financial Officer Jane Henderson reported routine open-market stock sales under a pre-arranged Rule 10b5-1 trading plan. On April 1, 2026, she sold 900 shares of common stock at a weighted average price of $84.46 and 1,100 shares at a weighted average price of $85.46, across multiple trades within disclosed price ranges. After these sales, she held 177,371 shares of common stock directly.
Apogee Therapeutics’ Chief Financial Officer Jane Henderson reported an open‑market sale of 2,000 shares of common stock at $85.00 per share. The transaction took place on March 25, 2026. After this sale, she directly holds 179,371 shares of Apogee common stock.
According to a footnote, this transaction was executed under a pre‑arranged Rule 10b5‑1 trading plan adopted on September 2, 2025. Such plans allow insiders to sell shares according to a preset schedule, reducing the role of day‑to‑day discretion in timing.
Apogee Therapeutics’ major shareholder Fairmount Funds and its principals report updated ownership just below 10% of the company. Fairmount and affiliates disclose beneficial ownership of up to 9.84% and 9.99% of Apogee’s common stock through a mix of common and non-voting common shares, plus vested options, all subject to a 9.99% beneficial ownership cap. Fund II also entered a 60-day lock-up, agreeing not to sell Apogee securities without underwriter consent following the company’s March 26, 2026 underwritten public offering, and did not purchase securities in that offering.
Apogee Therapeutics Inc amendment to a Schedule 13G/A reports that The Vanguard Group beneficially owns 0 shares of Common Stock, representing 0% of the class following an internal realignment described under SEC Release No. 34-39538. The filing explains certain Vanguard subsidiaries will report separately after the realignment. The form is signed by Ashley Grim on 03/26/2026.
Apogee Therapeutics, Inc. entered an underwriting agreement to issue and sell 5,000,000 shares of common stock at $70.00 per share. Underwriters were granted a 30-day option to buy up to 750,000 additional shares, which was exercised in full on March 25, 2026.
Net proceeds from the offering, including the exercised option, are expected to be approximately $377.4 million after underwriting discounts, commissions and estimated expenses. The transaction is being conducted under an existing shelf registration statement, with a final prospectus supplement filed on March 25, 2026, and is expected to close on March 26, 2026.
Apogee Therapeutics, Inc. is conducting a registered public offering of 5,000,000 shares of its voting common stock at a public offering price of $70.00 per share. The offering is expected to deliver approximately $329.0 million in proceeds to Apogee, before expenses, and the underwriters have a 30-day option to purchase up to an additional 750,000 shares.
The company estimates pro forma net tangible book value per share of $16.64 after this offering, implying immediate dilution of $53.36 per share to new investors. Apogee intends to use net proceeds to fund preclinical studies, clinical trials, manufacturing, commercial readiness, R&D, capital expenditures, working capital and general corporate purposes, and estimates the combined cash resources will fund operations into the first quarter of 2029 under current plans.
APGE reported a Form 144 notifying the sale of 6,000 restricted shares of Common Stock by Jane Henderson. The filing lists four 10b5-1 sales across 01/02/2026, 01/06/2026, 02/02/2026, and 03/02/2026 with per-trade share counts of 6,000, 2,000, 2,000 and 2,000 respectively and reported proceeds per trade in the filing.
Apogee Therapeutics, Inc. is offering $300,000,000 of its voting common stock in a registered underwritten offering, with the underwriters holding a 30-day option to purchase an additional $45,000,000 of shares.
The prospectus supplement states proceeds will be received by the issuer and that net proceeds are intended to fund preclinical studies, clinical trials, manufacturing, commercial readiness, research and development, capital expenditures, working capital and general corporate purposes. Shares outstanding were 69,038,943 as of December 31, 2025.
Apogee Therapeutics reported positive 52-week maintenance results from Part A of its Phase 2 APEX trial of zumilokibart (APG777) in moderate-to-severe atopic dermatitis. At 3- and 6‑month dosing intervals, 75% and 85% of patients maintained EASI‑75, and 86% and 78% maintained vIGA 0/1, showing durable disease control with infrequent injections.
The 360 mg subcutaneous regimen produced deepening responses across lesion and itch endpoints in both initial 16‑week responders and the full treated population, with a safety profile generally in line with other agents in the class. APEX Part B, a 347‑patient, placebo‑controlled dose‑optimization study, is expected to deliver 16‑week data in the second quarter of 2026.
Based on these data and the anticipated Part B induction results, the company plans to start Phase 3 trials in the second half of 2026, targeting a potential commercial launch in 2029 in what it believes could be a $50 billion atopic dermatitis market.